San Francisco

E1 Ventures is a systematic, stage-agnostic venture capital firm based in Silicon Valley that uses proprietary algorithms, data science, and extensive datasets to identify prime investment opportunities in deep tech. The firm invests across artificial intelligence, biotechnology, blockchain, energy, space exploration, fintech, augmented reality/virtual reality, and other frontier technology sectors. Their data-driven approach involves analyzing historical venture data to identify characteristics that signal future success, using machine learning to uncover patterns that escape conventional investment methods. E1 Ventures focuses primarily on early-stage technology startups building transformative solutions across multiple emerging technology domains.

Starship Ventures is a San Francisco-based venture capital firm founded in 2017 that invests in deep tech companies solving humanity's grand challenges of the 21st century. With over $30 million raised for their debut fund under General Partner Sean Hoge, Starship empowers contrarians turning science fiction into reality across advanced materials, aerospace, geoengineering, satellite constellations, AI, logistics, and energy. The firm's advisory board includes David Holz, founder of MidJourney and co-founding CTO of Leap Motion, along with a former VP of Propulsion at SpaceX with 12 years of experience. Starship has led investments in companies like Pipedream Labs, demonstrating their commitment to backing transformative deep tech ventures.

8090 Industries is a venture capital firm leading the next industrial revolution, partnering with over 20 global conglomerates to invest in and accelerate category-defining businesses. Co-founded by Kerem Ozmen and Rayyan Islam in 2022, the firm backs pioneers transforming the industrial complex with breakthrough technologies across decarbonization, aerospace, defense, and deep tech. Their portfolio includes investments in Oklo (advanced nuclear microreactors), Quaise (terrawatt-scale geothermal energy), Cemvita Factory (bio-refineries decarbonizing heavy industry), and Infinium (sustainable electrofuels). With backing from billionaire families spanning natural gas, consumer goods, and mining, 8090 Industries has made over 50 investments in companies they believe will become the trillion-dollar businesses of tomorrow.

Actual VC is a GCC-based venture capital firm managing a $400 million entrepreneur-managed global fund dedicated to empowering deep tech startups through strategic investment and comprehensive support. With a focus on material science, life sciences, and information sciences, Actual VC partners closely with founders, providing hands-on guidance and resources necessary to navigate the complexities of commercialization. The fund is uniquely managed by entrepreneurs who understand the intricacies of building successful ventures. By leveraging extensive expertise and industry relationships, Actual VC builds a collaborative ecosystem connecting entrepreneurs with key stakeholders, driving technological advancement and long-term value while prioritizing investments that create positive social and environmental impacts alongside financial returns.

Reliable Robotics is bringing FAA-certifiable autonomy to commercial and defense aviation with technology designed to work on any aircraft, in any airspace, directly addressing the most common causes of aviation incidents. Founded in 2017 by Robert Rose and Juerg Frefel, the company achieved a historic milestone in November 2023 with the first-ever flight of a Cessna 208B Caravan with no one on board, supervised by a remote pilot 50 miles away. The FAA formally accepted their certification plan in 2023 using existing regulations without special conditions. Reliable Robotics has secured a $17.4 million U.S. Air Force contract for automated aircraft and an additional multi-year IDIQ contract for advanced automation in airlift and refueling aircraft. The company also partners with NASA on demonstration flights evaluating autonomous operations in airport environments.

GenLab is a venture studio focused on Generative AI and DeepTech, building companies that leverage groundbreaking technologies to unlock unprecedented value. Recognizing that organizations failing to embrace these technologies risk falling behind, GenLab develops solutions tailored to specific industry needs that were unimaginable just five years ago. The studio allocates the majority of its investment capital into internal studio companies, with those startups often leveraging tools or technologies from their venture portfolio partners. By combining studio model company building with strategic venture investments, GenLab creates synergies between portfolio companies while shaping tomorrow's innovations today.

Gigascale Capital invests in sectors decisive for climate impact where deep tech meets the physical economy, solves real problems, and makes modern life better. The firm targets companies in early-stage commercialization phases, recognizing that in climate technology, MVPs look like pilot plants, scale demands capex, and commercialization is complex. Founded by investors with hands-on experience operating physical and R&D-driven companies, Gigascale provides patient capital and operational expertise for deep technology companies transitioning from development to commercial scale in climate-critical sectors including water technology, solar energy, construction materials, and industrial processes. The team combines deep commercialization expertise with ecosystem access to accelerate traction for portfolio companies.

SiPhox Health is a biotechnology company founded by former MIT researchers that is revolutionizing at-home health diagnostics through silicon photonics technology. The company has developed a blood testing system the size of a coffee maker that can produce precise readings for over 20 biomarkers related to hormonal balance, inflammation, cardiovascular health, and metabolic fitness. While their chip-based device pursues FDA clearance, SiPhox provides mail-in blood testing to thousands of people with chronic diseases using an innovative EasyDraw device that collects blood samples from the upper arm without needles or finger pricks. Their Burlington, Massachusetts facility can manufacture 10,000 cartridges per month. Starting at $125, SiPhox membership provides access to comprehensive biomarker testing including cholesterol panels, thyroid function, inflammatory markers, and hormone levels.